Prognostic Value of Peripheral Blood Parameters in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
Overview
This study evaluates the prognostic significance of peripheral blood parameters in breast cancer patients undergoing neoadjuvant chemotherapy. It highlights the association of inflammatory markers with treatment response and long-term outcomes, suggesting their potential utility in clinical practice.
Background
Breast cancer is a leading cause of cancer-related mortality among women, emphasizing the need for effective prognostic tools. The role of inflammatory markers in cancer progression and treatment response has gained attention, yet their clinical significance remains underexplored. Understanding these associations could enhance patient management and outcomes in breast cancer therapy.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
Elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with worse disease-free survival (DFS) and overall survival (OS) in breast cancer patients.
High platelet distribution width (PDW) and mean platelet volume (MPV) levels correlate with poor prognosis in breast cancer.
Increased NLR within the first year of treatment is linked to poor survival outcomes in triple-negative breast cancer patients.
Peripheral blood biomarkers may serve as prognostic indicators for systemic chemotherapy response and recurrence in breast cancer.
Limitations in previous studies include small sample sizes and short follow-up periods, which affect the interpretation of peripheral blood biomarkers.
Clinical Implications
Healthcare professionals should consider the assessment of peripheral blood parameters as part of the prognostic evaluation in breast cancer patients undergoing neoadjuvant chemotherapy. These markers may provide valuable insights into treatment response and long-term outcomes, aiding in personalized patient management.
Conclusion
The study underscores the potential of peripheral blood parameters as prognostic tools in breast cancer, warranting further investigation to validate their clinical utility. Enhanced understanding of these biomarkers could improve treatment strategies and patient outcomes.
by Tae-in Yoon, Seunghee Baek, Ji hyeon Lee, Tae Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
